Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: A clinical trial

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Casanova, Gislaine ^a,b   Spritzer, Poli Mara ^a,b,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b National Institute of Hormones and Women's Health   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Early postmenopause; Hormone therapy; Lipid profile; Micronized progesterone; Non oral estrogen

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; ESTROGEN THERAPY; FEMALE; HUMAN; OUTCOME ASSESSMENT; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVAGINAL; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; RISK FACTORS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84867136665     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-133     Document Type: Article

References (22)

1. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Sare GM, Gray LJ, Bath PM, Eur Heart J 2008 29 2031 2041 10.1093/eurheartj/ehn299 18599555
2. Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. Sherwin BB, Grigorova M, Fertil Steril 2011 96 399 403 10.1016/j.fertnstert.2011.05.079 21703613
3. Progestogen use in women approaching the menopause and breast cancer risk. Campagnoli C, Ambroggio S, Lotano MR, Peris C, Maturitas 2009 62 338 342 10.1016/j.maturitas.2008.10.017 19118958
4. Different cardiovascular effects of progestins according to structure and activity. Nath A, Sitruk-Ware R, Climacteric 2009 12 Suppl 1 96 101 19811251
5. Progestogens: effects on clinical and biochemical parameters in postmenopausal women. Archer DF, Menopause 2005 12 484 487 10.1097/01.gme. 0000177319.31629.52 16145299 (Pubitemid 41362070)
6. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA, Bush TL, Diabetes Care 1998 21 1589 1595 10.2337/diacare.21.10.1589 9773716 (Pubitemid 28449793)
7. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, Barrett-Connor E, Greendale GA, Am J Med 2006 119 167 161 e168
8. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Dubey RK, Imthurn B, Barton M, Jackson EK, Cardiovasc Res 2005 66 295 306 10.1016/j.cardiores.2004.12.012 15820198 (Pubitemid 40471044)
9. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Canonico M, Plu-Bureau G, Scarabin PY, Maturitas 2011 70 354 360 10.1016/j.maturitas.2011.10.002 22024394
10. One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension. Spritzer PM, Vitola D, Vilodre LC, Wender MC, Reis FM, Ruschel S, Castro I, Exp Clin Endocrinol Diabetes 2003 111 267 273 12951632 (Pubitemid 37040108)
11. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? Bukowska H, Stanosz S, Zochowska E, Millo B, Sieja K, Chelstowski K, Naruszewicz M, Metabolism 2005 54 72 78 10.1016/j.metabol.2004.07.015 15562383 (Pubitemid 39572460)
12. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. JAMA 2002 288 321 333 10.1001/jama.288.3.321 12117397 (Pubitemid 34761611)
13. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, et al. Fertil Steril 2004 81 1498 1501 10.1016/j.fertnstert.2004.02.095 15193467 (Pubitemid 38748989)
14. Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Shufelt CL, Johnson BD, Berga SL, Braunstein GD, Reis SE, Bittner V, Yang Y, Pepine CJ, Sharaf BL, Sopko G, et al. Menopause 2011 18 943 950 10.1097/gme.0b013e3182113672 21532511
15. Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the "timing hypothesis". Sowers MR, Randolph J Jr, Jannausch M, Lasley B, Jackson E, McConnell D, Arch Intern Med 2008 168 2146 2153 10.1001/archinte.168. 19.2146 18955645
16. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Seely EW, Walsh BW, Gerhard MD, Williams GH, Hypertension 1999 33 1190 1194 10.1161/01.HYP.33.5.1190 10334810 (Pubitemid 29230972)
17. Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials. Bea JW, Zhao Q, Cauley JA, LaCroix AZ, Bassford T, Lewis CE, Jackson RD, Tylavsky FA, Chen Z, Menopause 2011 18 44 52 10.1097/gme.0b013e3181e3aab1 20689466
18. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Kwok S, Selby PL, McElduff P, Laing I, Mackness B, Mackness MI, Prais H, Morgan J, Yates AP, Durrington PN, Sci FM, Clin Endocrinol (Oxf) 2004 61 760 767 10.1111/j.1365-2265.2004.02166.x (Pubitemid 40006798)
19. Evaluation of the effects of various gestagens on insulin sensitivity, using homeostatic model assessment, in postmenopausal women on hormone replacement therapy. Dansuk R, Unal O, Karsidag YK, Turan C, Gynecol Endocrinol 2005 20 1 5 10.1080/09513590400020880 15969239 (Pubitemid 40445233)
20. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Menon DV, Vongpatanasin W, Treat Endocrinol 2006 5 37 51 10.2165/00024677-200605010-00005 16396517 (Pubitemid 43096063)
21. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA, J Clin Endocrinol Metab 2008 93 1702 1710 10.1210/jc.2007-2193 18303079 (Pubitemid 351656508)
22. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. Casanova G, Radavelli S, Lhullier F, Spritzer PM, Fertil Steril 2009 92 605 612 10.1016/j.fertnstert.2008.06.049 18706557